NeOnc Technologies (NTHI) vs Stablecoin Development (SDEV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Stablecoin Development (SDEV) has outperformed NeOnc Technologies (NTHI) over the past year, losing 76.1% versus a loss of 76.8%. NeOnc Technologies is the larger company by market cap ($80.1 million vs $79.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NTHI | SDEV |
|---|---|---|
| Share price | $2.78 | $1.54 |
| Market cap | $80.08M | $79.70M |
| 1-day change | +9.88% | -22.61% |
| YTD return | -66.38% | -94.54% |
| 1-year return | -76.79% | -76.12% |
| 5-year return | — | -99.95% |
| EPS (TTM) | $-2.13 | $-21.13 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.09 | $99.75 |
| 52-week low | $2.50 | $0.78 |
| Distance from 52-week high | -77.01% | -98.46% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +511.51% | — |
| Average volume | 195.17K | 11.93M |
| Shares outstanding | 28.81M | 51.75M |
| Employees | 5 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About NeOnc Technologies
NTHI stock →NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
About Stablecoin Development
SDEV stock →Stablecoin Development Corporation engages in the accumulation and holding of digital assets for participation in blockchain-based networks. The company focuses on the accumulation, holding, and deployment of SKY, a protocol token of the decentralized Sky Protocol.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
NTHI vs SDEV FAQ
Which is bigger, NeOnc Technologies or Stablecoin Development?
NeOnc Technologies (NTHI) is larger, with a market capitalization of $80.08M compared with $79.70M for Stablecoin Development (SDEV).
Which stock has performed better over the past year, NTHI or SDEV?
SDEV returned -76.12% over the past 12 months, compared with -76.79% for NTHI (price return, excluding dividends). Past performance does not predict future results.
Are NeOnc Technologies and Stablecoin Development in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.